Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today a collaboration between Esoterix Clinical Trials Services, a division of LabCorp, and Clearstone Central Laboratories, a global central laboratory specializing in drug development and pharmaceutical services.
“This collaboration combines the complementary strengths of two leading central laboratories to support drug development”
The collaboration provides LabCorp with access to Clearstone's global network of labs, including China, France, Singapore and Canada, in addition to LabCorp's existing labs in the United States and Belgium. The companies will collaborate on providing standardized central laboratory testing for clinical trials to their respective clients. The transaction also provides LabCorp access to Clearstone's clinical trials management system APOLLO CLPM™, enhancing the ability of clients to conveniently send, receive and manage data.
"This collaboration combines the complementary strengths of two leading central laboratories to support drug development," said David P. King, Chairman and Chief Executive Officer of LabCorp. "The transaction is an important milestone as it enhances LabCorp's clinical trials central lab offering to customers in key geographies and advances the Company's companion diagnostics and personalized medicine strategy."